Phase I, Open Label Dose Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Latest Information Update: 11 Feb 2024
At a glance
- Drugs UCART 123 (Primary) ; Alemtuzumab; Cyclophosphamides; Fludarabine; Tocilizumab
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; First in man
- Acronyms AMELI-01
- Sponsors Cellectis
- 31 Jan 2024 Planned End Date changed from 1 Mar 2023 to 1 Dec 2024.
- 31 Jan 2024 Planned primary completion date changed from 1 Mar 2023 to 1 Dec 2024.
- 03 Aug 2023 According to a Cellectis media release, results were presented at the American Society of Gene and Cell Therapy (ASGCT) 2023 annual meeting.